Schedules for the follow-up (FU) of bladder cancer patients are predominantly based on studies with low level of evidence and the resulting guidelines' recommendations that are often founded on expert consensus. FU of non-muscle invasive bladder cancer (NMIBC) includes cystoscopy and cytology as standard, and imaging modalities to a lower extent. FU of muscle-invasive bladder cancer (MIBC) depends primarily on the therapeutic modality chosen and on the stage of disease. In this scenario, FU is complemented by functional and quality of life related aspects. These apply even more for FU in palliative situations. Here, the individual focus is on examinations that might have a consequence in terms of survival and/or symptom relief.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Der Urologe. Ausg. A. 2018 Apr 16 [Epub ahead of print]
P Olbert, P J Goebell, A Hegele
Praxis und Belegabteilung für Urologie und Andrologie, Brixsana Private Clinic, Julius Durst Str. 28, 39042, Brixen, Italien. ., Urologische und Kinderurologische Klinik, Friedrich-Alexander Universität, Erlangen, Deutschland., Klinik für Urologie und Kinderurologie, Universitätsklinikum Marburg UKGM, Marburg, Deutschland.